Protara Therapeutics (TARA)
(Delayed Data from NSDQ)
$3.11 USD
-0.04 (-1.27%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $3.12 +0.01 (0.32%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TARA 3.11 -0.04(-1.27%)
Will TARA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TARA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARA
Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy
TARA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TARA
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ...
Catalio Capital Management Raises Over $400M to Invest in Innovative Healthcare Companies in ...
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ...
Protara Therapeutics (TARA) Added to Russell 3000 Index
Protara Therapeutics added to the Russell 3000 index